Anti‐inflammatory activity of topical THC in DNFB‐mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors

∆9‐Tetrahydrocannabinol (THC), the active constituent of Cannabis sativa, exerts its biological effects in part through the G‐protein‐coupled CB1 and CB2 receptors, which were initially discovered in brain and spleen tissue, respectively. However, THC also has CB1/2 receptor‐independent effects. Because of its immune‐inhibitory potential, THC and related cannabinoids are being considered for the treatment of inflammatory skin diseases. Here we investigated the mechanism of the anti‐inflammatory activity of THC and the role of CB1 and CB2 receptors.

[1]  J. Flores,et al.  The orphan receptor GPR55 drives skin carcinogenesis and is upregulated in human squamous cell carcinomas , 2013, Oncogene.

[2]  B. Igyártó,et al.  Early immune events in the induction of allergic contact dermatitis , 2012, Nature Reviews Immunology.

[3]  T. Jakob,et al.  Mechanisms of chemical‐induced innate immunity in allergic contact dermatitis , 2011, Allergy.

[4]  Andreas Zimmer,et al.  Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors. , 2011, Immunobiology.

[5]  C. Albanesi.  Keratinocytes in allergic skin diseases , 2010, Current opinion in allergy and clinical immunology.

[6]  D. Kendall,et al.  Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. , 2010, Immunobiology.

[7]  K. Altmann,et al.  Falcarinol is a covalent cannabinoid CB1 receptor antagonist and induces pro-allergic effects in skin. , 2010, Biochemical pharmacology.

[8]  T. Bisogno,et al.  Protective role of palmitoylethanolamide in contact allergic dermatitis , 2009, Allergy.

[9]  M. Nagarkatti,et al.  Cannabinoids as novel anti-inflammatory drugs. , 2009, Future medicinal chemistry.

[10]  D. Shander,et al.  Non-neuronal expression of transient receptor potential type A1 (TRPA1) in human skin. , 2009, The Journal of investigative dermatology.

[11]  J. Szepietowski,et al.  Cannabinoid system in the skin – a possible target for future therapies in dermatology , 2009, Experimental dermatology.

[12]  R. Ross.  The enigmatic pharmacology of GPR55. , 2009, Trends in pharmacological sciences.

[13]  S. Werner,et al.  Attenuation of Allergic Contact Dermatitis Through the Endocannabinoid System , 2007, Science.

[14]  E. Williamson,et al.  Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. , 2007, Journal of dermatological science.

[15]  T. Luger,et al.  [Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus]. , 2006, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[16]  T. Sugiura,et al.  Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2-arachidonoylglycerol. , 2006, European journal of pharmacology.

[17]  T. Klein.  Cannabinoid-based drugs as anti-inflammatory therapeutics , 2005, Nature Reviews Immunology.

[18]  D. Osei-Hyiaman,et al.  Evidence for novel cannabinoid receptors. , 2005, Pharmacology & therapeutics.

[19]  D. McKemy,et al.  Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1 , 2004, Nature.

[20]  A. Finazzi-Agro’,et al.  The Endocannabinoid System in Human Keratinocytes , 2003, Journal of Biological Chemistry.

[21]  T. Bonner,et al.  Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. , 2000, European journal of pharmacology.

[22]  T. Klein,et al.  Delta9-tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. , 1998, The Journal of pharmacology and experimental therapeutics.

[23]  A. Bloom,et al.  Nonclassical and Endogenous Cannabinoids: Effects on the Ordering of Brain Membranes , 1997, Neurochemical Research.

[24]  P. Casellas,et al.  Cannabinoids enhance human B‐cell growth at low nanomolar concentrations , 1995, FEBS letters.

[25]  M. Denda,et al.  Roles of transient receptor potential proteins (TRPs) in epidermal keratinocytes. , 2011, Advances in experimental medicine and biology.

[26]  C. Newton,et al.  Cannabinoids and the immune system. , 2001, Pain research & management.

[27]  G. Cabral,et al.  Cannabinoids inhibit LPS‐inducible cytokine mRNA expression in rat microglial cells , 2000, Glia.

[28]  C. Newton,et al.  The cannabinoid system and cytokine network. , 2000, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[29]  C. Newton,et al.  The effect of delta-9-tetrahydrocannabinol and 11-hydroxy-delta-9-tetrahydrocannabinol on T-lymphocyte and B-lymphocyte mitogen responses. , 1985, Journal of immunopharmacology.